Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538065 · ClinicalTrials.gov registry record · NA
NUDGE-EHR Replication Trial at Mass General Brigham
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 201
- Enrollment target
NCT05538065: Completed NA study, sponsored by Brigham and Women's Hospital.
NCT05538065 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 201 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05538065, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
Study Summary
Prescribing of potentially unsafe medications for older adults is extremely common; benzodiazepines and sedative hypnotics are, for example, key drug classes frequently implicated in adverse health consequences for vulnerable older adults, such as confusion or sedation, leading to hospitalizations, falls, and fractures. Fortunately, most of these consequences are preventable. Physicians' lack of awareness of alternatives, ambiguous practice guidelines, and perceived pressure from patients or caregivers are among the reasons why these drugs are used more than might be optimal. Reducing inappropriate use of these drugs may be achieved through decision support tools for providers that are embedded in electronic health record (EHR) systems. While EHR strategies are widely used to support the informational needs of providers, these tools have demonstrated only modest effectiveness at improving prescribing. The effectiveness of these tools could be enhanced by leveraging principles of behavioral economics and related sciences.
Primary Outcome
This outcome is measured as a composite of 1) discontinuation of study high-risk medications (i.e., active discontinuation or lack of an order during follow-up) or 2) ordering a dose taper (for benzodiazepine or sedative hypnotics) using EHR data by the primary care provider included in the study arm. If any of these actions occurred by the primary care provider, then the patient was considered to have had a change in prescribing (i.e., a reduction in inappropriate prescribing). This outcome was
Interventions
- OTHER Follow-up booster Alert
- OTHER Pre-commitment
- OTHER Enhanced Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2024-06-15 |
| Phase | NA |
What the finished NCT05538065 record still lists
NCT05538065 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 3 interventions - of which Follow-up booster Alert is the first listed.
NCT05538065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05538065 about?
NCT05538065 is a clinical study titled "NUDGE-EHR Replication Trial at Mass General Brigham". Prescribing of potentially unsafe medications for older adults is extremely common; benzodiazepines and sedative hypnotics are, for example, key drug classes frequently implicated in adverse health consequences for vulnerable older adults, such as confusion or sedation, leading to hospitalizations, ...
What is the current status of trial NCT05538065?
This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2022-11-10. Estimated completion is 2024-06-15.
What interventions are being tested in trial NCT05538065?
The interventions under investigation include: Follow-up booster Alert (OTHER), Pre-commitment (OTHER), Enhanced Alert (OTHER).
Who is sponsoring clinical trial NCT05538065?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05538065's enrollment target sits among peer trials
201 506th of 2000 higher than 1,495 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI